To test the reliability and validity of the Chinese version of the general medication adherence scale (GMAS) in patients with nontuberculous mycobacterial pulmonary disease(NTM-PD).

Patients with NTM-PD treated in Wuxi Fifth Hospital affiliated with Jiangnan University from February 2023 to September 2024 were selected as research objects to conduct a questionnaire survey to test the reliability and validity of the Chinese version of GMAS.

A total of 281 patients were included in the study. The Cronbach's α coefficient of the Chinese version of the universal medication compliance scale was 0.890, and the Cronbach's α coefficient of each dimension was 0.834-0.890. The broken half reliability was 0.806, the split-half reliability of each dimension was 0.834-0.870, and the test-retest reliability was 0.896. Three common factors were extracted by exploratory factor analysis, and the cumulative variance contribution rate was 76.244%. Confirmatory factor analysis showed that the model had a good fit, χ²/df=1.583, GFI=0.928, AGFI=0.884, NFI=0.934, TLI=0.965, CFI=0.974, TLI=0.965, RMSEA=0.063, and had good convergent validity and discriminant validity.

The Chinese version of GMAS has good reliability and validity in NTM-PD patients, mainly middle-aged and elderly people, and can be used to evaluate the level of medication compliance in this population.